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REVIEW
Proteomics Technologies for the Study of Autoimmune Disease
William H. Robinson, Lawrence Steinman, and Paul J. Utz
Introduction
Autoimmune disease affects 3% of the US pop-
ulation, and likely a similar percentage of the population
of the industrialized world (1). Although remarkable
progress toward understanding immune function has
been made over the last 4 decades in terms of the role of
the major histocompatibility complex and the nature of
lymphocyte antigen receptors that confer specificity to
autoimmune responses, understanding of the underlying
dysregulation and autoimmune response specificity re-
mains limited. For certain autoimmune diseases, includ-
ing Sjo ¨gren’s syndrome and systemic lupus erythemato-
sus (SLE), candidate autoantigens have been identified
but their exact roles in the initiation, perpetuation, and
pathophysiology are not well understood. For other
autoimmune diseases, including rheumatoid arthritis
(RA) and psoriasis, the targeted autoantigens remain
unidentified despite extensive experimental efforts. Ar-
ray and other multiplex screening technologies represent
powerful tools for studying the pathophysiology and
specificity of autoimmune responses.
The advent of DNA microarray technology dur-
ing the last decade has led to an explosion of studies
aimed at identifying novel messenger RNA (mRNA)
transcripts, or patterns of transcripts, that are transcrip-
tionally up- or down-regulated in association with a
particular disease or phenotype. As the availability and
costs of such “DNA chips” improve, it is anticipated that
transcriptional profiling will gain even greater promi-
nence in autoimmune disease research. “Spotted” DNA
microarrays are now available at many university and
industry laboratories and are providing a wealth of
information regarding the underlying pathophysiology
of autoimmune disease (2). However, use of RNA
transcriptional profiling has important limitations and is
likely unable to provide the comprehensive understand-
ing of autoimmune processes that would be necessary to
develop next-generation therapies.
RNA transcriptional profiling alone is an inade-
quate method for studying human autoimmune disease,
for several reasons. First, diseases manifest not at the
level of RNA transcription, but rather at the level of the
protein. Second, there is a frequently nonpredictive
correlation between RNA expression and protein ex-
pression and function (3,4). Messenger RNA undergoes
a variety of processing events that can profoundly affect
cell phenotype yet are not revealed in current transcrip-
tional profiles. For example, mRNA encoding certain
apoptosis-regulatory molecules exists in 2 or more alter-
native splice forms encoding proteins with opposing
functions (e.g., proapoptotic isoforms such as Bcl-xS and
protective isoforms such as Bcl-xL) (5). Translation of
mRNA into protein is also regulated by translational
regulatory elements such as 3 mRNA AU–rich ele-
ments and by addition of poly(A) tails of various lengths
(6–8). Third, protein function can be regulated by
posttranslational modifications by enzymes such as ki-
nases or proteases. Finally, autoimmune responses are
regulated by autoantigen-specific T and B lymphocytes
expressing distinct and heterogeneous antigen receptors
that are not easily examined by transcriptional profiling.
Many of these limitations can be circumvented by
direct study of the expression and function of proteins
encoded by these RNA transcripts. The large-scale study
of the expression, function, and interactions of proteins
expressed in a tissue or organism is termed “proteomics”
(9). With our entrance into the “post-genomics era,” it is
essential to develop novel tools with which protein
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885expression and protein–protein interactions can be ex-
plored. This report will review proteomics technologies
under development, with a focus on human autoimmune
disease. Readers interested in more comprehensive de-
scriptions of proteomics are referred to several excellent
reviews by other authors (9–13).
Recent advances in the detection of protein—protein
interactions
The ideal assay for detecting proteins and their
interactions should be sensitive, specific, and reproduc-
ible. Many such assays are already available, including
Western blotting, 2-dimensional gel electrophoresis, and
enzyme-linked immunosorbent assay (ELISA). How-
ever, these assays are not amenable to “multiplex ana-
lysis” whereby one can simultaneously screen thousands
of individual proteins for their ability to interact with
other molecules. Other techniques, including
microfluidics- and mass spectroscopy–based approaches,
are under active development but are unlikely to be
widely available to academic and industry researchers in
the near future. We will briefly describe these techniques
before focusing the remainder of the review on spotted
antigen microarray technology, a technique that is rela-
tively straightforward and utilizes simple protocols and
widely available equipment. We will specifically discuss
the application of antigen arrays for the study of auto-
antibodies as well as for development and selection of
antigen-specific therapies for autoimmune disease.
A commonly utilized method in proteomics is the
separation of complex mixtures of proteins (e.g., cell
lysates prepared from cell lines, primary cell cultures, or
tissue) by 2-dimensional gel electrophoresis. Individual
proteins are visualized by staining (silver or other stain-
ing methods) or by Western blot analysis using an
antibody or autoimmune serum sample. This approach is
readily amenable to identification of novel reactivities,
such as the discovery of new autoantigens recognized by
serum from patients with autoimmune disease, and it is
fairly easy to perform by laboratory personnel familiar
with basic biochemistry. Moreover, the technique is now
highly standardized and facilitates purification of reac-
tive proteins by excising a particular reactive spot and
subjecting it to amino acid sequence analysis, mass
spectroscopy, or tandem mass spectroscopy. A major
drawback is that the identity of a reactive protein is not
immediately known based on its position on the gel (see
below), and the limits of detection are below those
governing the utility of other techniques (14).
Genetic plaque- and colony-based strategies pro-
vide a powerful approach but frequently require large
quantities of patient samples and cannot be used to
identify posttranslational protein modifications. A vari-
ation of this strategy involves “living arrays,” utilizing a
modified yeast 2-hybrid system (15), to identify protein–
protein interactions (16). Such “living arrays” can detect
protein–protein interactions in living eukaryotic cells,
using a genetic screen that produces a functional read-
out (16). This method has the distinct advantage of
being more sensitive than traditional library screening
methods, allowing dissection of biochemical pathways
such as signal transduction and enzymatic pathways, and
identification of components of multi-subunit com-
plexes. Application of this approach to identify compo-
nents of autoantigens, many of which exist in complex
with other proteins or RNA molecules (17), will un-
doubtedly be attempted.
Microfluidics approaches have also been devel-
oped, to enable high-throughput screening of biomolec-
ular interactions. Microfluidics utilizes microchannels
etched in a solid support to mix solutions containing
distinct biologic and/or other molecules, in order to
study the interactions of these molecules. Small volumes
of reactants (e.g., proteins, drug candidates, nucleic
acids, biologic fluids) are subjected to electrokinetic flow
in a network of channels such that small “plugs” of
individual reactants are brought into contact with one
another within the network (18,19). Binding events are
observed as changes in the electrophoretic mobility of
the reactants (e.g., retarded mobility of an interacting
pair), which is usually observed by ultraviolet absorption
or fluorescent detection (20). Microfluidics channels can
be fabricated in plastic, silicon, or other materials, using
lasers or photolithographic masks. A “microfluidic tec-
tonics” platform that takes advantage of many recent
advances in polymer chemistry, fluidics, and hydrogel
development has recently been described (21).
Fluidics approaches have several advantages over
spotted antigen array technology and other multiplex
proteomics techniques. With fluidics techniques, inter-
acting species are in solution phase at all times, elimi-
nating the binding of antigen to a surface (as part of a
well, matrix, or planar surface) that may disrupt impor-
tant immunologic epitopes. Fluidics approaches enable
real-time millisecond quantitation of binding kinetics. In
addition, they have the potential to enable sensitive
detection of low-affinity biomolecular interactions that
is not possible with other proteomics technologies in-
cluding surface plasmon resonance technologies, such as
Biacore. Fluidics methodologies are amenable to multi-
plex analysis through design of complex channel net-
works and use of microfabricated electrokinetic chan-
nels to direct flow and mixing of all possible
886 ROBINSON ET ALcombinations of molecules introduced into the network.
Several companies are developing “lab-on-a-chip” mi-
crofluidics technologies for multiplex proteomic analysis
(see www.aclara.com and www.calipertech.com), which
may become available to academic and industry labora-
tories in the future. A demonstration of this technology
can be found on the World Wide Web at http://
www.stanford.edu/group/microfluidics/.
One particularly attractive fluid-phase platform
was developed by Aclara, Inc. (Mountain View, CA).
Cleavable fluorescent reporters with unique electro-
phoretic mobilities are used to identify and quantify
binding interactions between molecules, including pro-
teins, using widely available capillary electrophoresis
equipment (see www.aclara.com).
Several groups are developing addressable
nanoparticle-based assays for multiplex analysis of RNA
transcripts, proteins, and antibodies. The Luminex sys-
tem involves use of 64 distinct sets of spectrally resolv-
able fluorescent beads (22). Each fluorescently addres-
sable set of beads is conjugated to a different antigen,
antibody, or oligonucleotide, incubated with the test
sample, and then analyzed using a benchtop flow cytom-
eter (22). Nanoparticles or beads can also be uniquely
tagged using cylindrical metal nanoparticles that serve as
“nanobarcode identification tags” (see www.surromed.
com) and other addressable tag–based systems. Others
have developed bead-based fiber-optic arrays for tran-
scriptional profiling (23). Bead-based approaches have
the potential to enable arrays of significantly greater
complexity than the 10
5 order of complexity that is
possible when using centimeter-size planar surfaces.
Bead-based methodologies are being refined and devel-
oped for use as large-scale peptide and protein arrays.
Protein and antigen array technologies currently under
development are listed in Table 1.
Antigen microarray technologies
The remaining discussion will focus on methods
for partitioning proteins at spatially resolvable positions,
either in wells, within 3-dimensional matrices, or on a
planar surface, unlike the methods described above. The
position and identity of each immobilized protein is
known, and the miniaturized format enables parallel
detection of thousands of unique proteins using sub-
microliter quantities of human serum. This provides a
distinct advantage over other techniques, such as phage
display or 2-dimensional gel electrophoresis, in which
the protein or peptide that is detected is unknown and
thus requires further analysis for identification (14,24).
In the late 1980s and early 1990s, Ekins and colleagues
Table 1. Protein and antigen array technologies
Array type
Arrayed
elements Surfaces Detection Applications Refs.
Proteins, polypeptides, and
peptides in spatially
addressable arrays
Proteins,
polypeptides,
peptides,
antibodies
Derivatized
glass,
membranes
Fluorescence,
chemiluminescence,
radioactivity
Detection of protein–protein,
protein–macromolecule,
protein–small molecule,
antigen–antibody, and enzyme–
substrate interactions
32,35–38,65
In situ–generated spatially
addressable arrays:
1) expressed polypeptides
2) photolithography-
generated
Polypeptides,
peptides
Derivatized
glass,
membranes
Fluorescence,
chemiluminescence
Detection of protein–protein,
protein–macromolecule,
protein–small molecule,
antigen–antibody, and enzyme–
substrate interactions
29,66
Living cell spatially
addressable arrays
Live cells
expressing
polypeptides
encoded by
transfected
expression
vectors
Gelatin-coated
glass, agar,
membranes
Fluorescence,
colorimetric
Detection of protein–protein,
protein–macromolecule,
protein-small molecule, antigen-
antibody, and enzyme-substrate
interactions
16,67
Particle arrays Antigens,
antibodies
Beads and
nanoparticles
Fluorescence,
microscopic
Detection of protein–protein,
protein–macromolecule,
protein–small molecule, and
antigen–antibody interactions
22
Microfluidics Micro-channels
for analysis
using
electrokinetic
flow
Channels
etched in
glass,
acrylic, or
other solid
supports
Fluorescence,
ultraviolet
absorption
Multiplexed analysis of binding
interactions
18,19
PROTEOMICS TECHNOLOGIES FOR AUTOIMMUNE DISEASE 887described a “multi-microspot multianalyte immunoas-
say” (25–27). Recently, several groups have reported
significant advances in the development and application
of protein and antigen array technologies, as described
below.
One simple method for performing parallel de-
tection of protein–protein interactions is with the use of
microtiter plates (e.g., by ELISA). Several groups have
begun using smaller and smaller wells (e.g., 384 or 1,536
well plates) for spatial resolution, while others have
developed arrays of microwells etched into silicon wafers
(13,28). Such technologies enable reactions to occur in
fluid phase within individual wells.
Various methods have been developed to fabri-
cate arrays by depositing samples at distinct and addres-
sable locations on solid surfaces, including “stamping,”
ink jet application, capillary spotting, and synthesis of
molecules directly on the array using photolithographic
masks or maskless fabrication with digital micromirrors
(13,29–31). Fodor and colleagues described use of pat-
terned, light-directed combinatorial chemical synthesis
for the generation of peptide and oligonucleotide arrays
(29). Ge developed a “Universal Protein Array” (UPA)
by applying proteins to nitrocellulose membranes in
order to detect molecular interactions between proteins,
as well as interaction of proteins with chemical ligands,
DNA, or RNA (32). Disadvantages of this UPA system
include its requirements for relatively large quantities of
purified antigen for spotting and samples to probe the
arrays, as well as use of radioisotope-based detection.
Others have developed and evaluated a “line immuno-
assay” in which antigens are deposited at discrete loca-
tions on strips of membrane, enabling consistent and
simultaneous detection of multiple autoantibody species
(33).
Figure 1 depicts a robotic capillary arrayer simi-
lar to the one developed in the laboratory of Dr. P. O.
Brown to fabricate DNA microarrays (34,35). Several
groups, including MacBeath and Schreiber at Harvard
University (36) and Haab, Dunham, and Brown at
Stanford University (35), developed methods utilizing
such robotic arrayers to deposit proteins onto micro-
scope slides in order to fabricate high-density protein
arrays. The protein arrays described by these investiga-
tors contain hundreds of different proteins attached to
the surface of microscope slides, where they are ana-
lyzed for interactions with other proteins, enzymes, or
drugs.
MacBeath and Schreiber demonstrated that sim-
ple protein arrays can be used to detect interactions of
immobilized proteins with antibodies, with cellular pro-
teins such as p50 nuclear factor B, and with protein–
drug complexes such as FK-BP12 and rapamycin (36).
They also demonstrated use of protein arrays to detect
the enzymatic activity of kinases, with a panel of specific
immobilized protein substrates. Haab et al characterized
the reactivities of 115 antibody–antigen pairs, demon-
strating that 50% of arrayed antigens and 20% of
immobilized antibodies could be robustly detected in
this format (35). A small subset of antibodies was
capable of detecting antigens in complex solutions at
Figure 1. Robotic microarrayer used to fabricate antigen microarrays.
A robotic microarrayer, similar to the one pictured, was developed by
Brown and colleagues to fabricate DNA microarrays and, more
recently, protein microarrays (34,35) (see http://cmgm.stanford.edu/
pbrown). Microcapillary spotting pins draw up antigen solutions
contained in microtiter plates and deposit each solution at a distinct
location on successive microscope slides. The spotted antigens attach
to the microscope slides electrostatically or covalently, or are physically
entrapped based on the surface chemistry of the slides. Commonly
used slide surface chemical materials include poly-L-lysine coatings,
gelatin coatings, acrylamide coatings, and silane-treated glass slides.
888 ROBINSON ET ALlevels that would allow their use in certain clinical
applications, including detection of human serum pro-
teins present at ng/ml quantities. Examples include
markers of ischemic injury (troponin, creatine kinase
MB), malignancy (prostate-specific antigen), and certain
cytokines (tumor necrosis factor , interleukin-1 [IL-1])
present at relatively high concentrations. Unfortunately,
most cytokines are present at pg/ml or lower concentra-
tions (IL-4, IL-10) and are thus not amenable to detec-
tion with current spotted antibody array systems. The
spotted antigen arrays developed by Haab et al enabled
sensitive detection of purified antibodies and antigens
diluted into complex solutions of proteins.
Joos et al described the construction of autoan-
tigen microarrays containing 18 prominent autoantigens
spotted onto surfaces including silane-treated glass
slides and nitrocellulose (37). Their arrays proved to be
sensitive and specific for detection of autoantibodies to
many of the spotted antigens, with as little as 40 fg
spotted protein still detectable for one of the protein
standards used. Bound antibodies were visualized using
a secondary antibody conjugated to horseradish peroxi-
dase prior to addition of a luminescent substrate, and
imaged using a charge-coupled device chemilumines-
cence camera.
To date, comprehensive autoantigen microarrays
that are capable of fluorescence detection of human
autoantibodies present in biologic fluids such as serum,
cerebrospinal fluid (CSF), or synovial fluid have not
been described. We therefore developed and refined
protein microarray technology to study the specificity of
the autoantibody response in murine and human auto-
immune diseases (38). Using a protocol modified from
those recently described by Haab et al (35) and
MacBeath and Schreiber (36), we used the robotic
arrayer depicted in Figure 1 to attach peptides, proteins,
nucleic acids, and protein complexes to distinct and
addressable locations on microscope slides. At each
antigen feature 1 nl of antigen solution is deposited,
producing a relatively uniform feature measuring 150
m in diameter. Individual arrays are incubated with
serum from autoimmune disease patients and controls,
washed, and incubated with secondary antibodies co-
valently conjugated to spectrally resolvable fluorescent
labels (such as Cy3 or Cy5). Alternatively, comparative
analysis can be performed by incubating arrays simulta-
neously with a reference and disease serum sample, each
directly labeled with a distinct, spectrally resolvable
fluorochrome as described by Haab et al (35). The slides
are analyzed using a fluorescence-based digital scanning
system. Antigen microarrays use simple protocols and
basic spotted DNA array equipment available at many
academic medical centers and industry laboratories.
Detailed protocols to fabricate and conduct antigen
microarray studies are presented in our report (38) and
can be found on the World Wide Web at http://
www.stanford.edu/group/antigenarrays.
An example of use of our first-generation antigen
arrays to characterize the specificity of the autoantibody
response in human SLE patients is presented in Figure
2. More recently, we have expanded our antigen arrays
Figure 2. Antigen array detection of autoantibodies specific for com-
mon autoantigens in systemic lupus erythematosus (SLE). Protein
arrays were fabricated by spotting common SLE antigens including
DNA, histone 2-A protein, and serine/arginine (SR) proteins onto
poly-L-lysine–coated glass microscope slides using a robotic microar-
rayer (34,35,38) (see Figure 1). Arrays were incubated with patient
serum followed by secondary antibody covalently conjugated to a
spectrally resolvable fluorescent label, and then scanned with a Gene-
Pix 4000B Array Scanner (Axon Instruments, Union City, CA). Shown
are scanned images of arrays incubated with serum from a healthy
control subject (A) and 2 SLE patients (B and C), followed by
Cy3-labeled anti-human Ig secondary antibody. In SLE patient 1,
autoantibodies specific for DNA (yellow circles) and SR proteins
(orange circles) are detected. SLE patient 2 has autoantibody reactiv-
ity primarily against DNA (yellow circles) and histone 2-A protein
(blue circles). The array-determined autoantibody profiles in these 2
SLE serum samples and the control sample are in exact concordance
with the specificities previously determined using traditional methods
including Western blot, enzyme-linked immunosorbent assay, and
immunoprecipitation analysis (68). Antibodies specific for influenza A
virus vaccine are detected in all samples (white circles). Spotted
antibodies specific for human IgG detect the presence of IgG in each
sample (red circles). Full details of the methods used to fabricate,
probe, and analyze these antigen microarrays are presented in ref. 38
and on the World Wide Web at http://www.stanford.edu/group/
antigenarrays and http://cmgm.stanford.edu/pbrown.
PROTEOMICS TECHNOLOGIES FOR AUTOIMMUNE DISEASE 889to include 200 distinct protein, peptide, nucleic acid,
and protein complex antigens targeted to humans with
various autoimmune diseases including RA, SLE, poly-
myositis, limited and diffuse scleroderma, primary bili-
ary sclerosis, and Sjo ¨gren’s syndrome (38). We have also
generated “myelin proteome” arrays containing 500
proteins and peptides derived from the myelin sheath
that are targeted in multiple sclerosis (MS) and its
animal model (experimental autoimmune encephalomy-
elitis [EAE]). We are using these arrays to characterize
specificity and epitope spreading and to guide selection
of antigen-specific therapies in EAE (Robinson WH, et
al: unpublished observations). We are also using our
myelin proteome arrays to characterize the specificity of
the autoantibody response in CSF and brain plaque–
eluted antibody from humans with MS.
A distinct advantage of our antigen array ap-
proach is that posttranslational modifications can be
readily detected. Casciola-Rosen et al and others have
proposed that such modifications may be important for
initiating autoantibody formation, and this technique
may be of use in further exploring this possibility (39–
42). Furthermore, antigen arrays enable repeat multi-
plex analysis of the specificity of the autoantibody
response against the same panel of putative autoanti-
gens in many consecutive patients.
The human genome encodes between 26,000 and
120,000 proteins, not counting multiple isoforms or
posttranslationally modified proteins (43). To produce,
purify, and spot every protein on individual arrays is a
daunting task. An interesting solution to this problem
has been proposed by Walter et al (13) and was pre-
sented at the February 2001 meeting of the Association
for Biomolecular Resource Facilities. These investiga-
tors have taken advantage of preexisting complementary
DNA (cDNA) libraries used for transcriptional profil-
ing, to produce polypeptides for microarray analysis
(44,45). In one format, His-tagged proteins are ex-
pressed in liquid bacterial cultures, purified using nickel
chromatography, and applied to a polyvinylidene diflu-
oride surface using ink-jet technology prior to probing
the array with an antibody solution. The investigators
report robust detection of as little as 10 pg of a test
protein (GAPDH), demonstrating the potential feasibil-
ity of this technology for large-scale production of
protein microarrays using existing cDNA libraries (13).
They are applying this technology as an antibody speci-
ficity screen to identify novel autoantigens targeted by
autoantibodies in the sera of patients with Crohn’s
disease and ulcerative colitis (13).
Future directions
Application of proteomics technologies for diag-
nosis. One potential application of protein array tech-
nology is in clinical diagnostic testing. Most current
rheumatologic tests rely on ELISA-based methodology
in which individual tests (e.g., for autoantibodies against
Sm, Ro, or RNP) are performed on multiple different
serum samples within individual wells in the same mi-
crotiter plate (17). Although the transition may take
years to decades, antigen microarrays, whether on pla-
nar surfaces or in other formats that are yet to be
described, will enable multiplex parallel testing that will
most likely replace currently utilized autoantibody test-
ing methods. As with any new diagnostic test, more
extensive validation using thousands of serum samples
and demonstration of consistent and reproducible re-
sults will be necessary before this technology reaches the
clinic. Moreover, certain autoantigens are not amenable
to this detection format (Robinson WH, et al: unpub-
lished observations), suggesting that continued efforts to
optimize antigen production and purification, planar
surface chemistry, fluorescence detection and quantita-
tion, and analysis of complex data sets are needed.
Use of proteomics technologies to study the spec-
ificity and pathophysiology of autoimmune responses.
The greatest immediate impact of proteomics technol-
ogy in the field of rheumatology will be in the study of
autoantibodies. This technology allows the rapid, simul-
taneous detection of thousands of autoantibody reactiv-
ities using 1 l of serum per array. We are currently
using protein and peptide microarrays to study inter-
and intramolecular epitope spreading of the humoral
immune response over time, both in animal models of
autoimmune disease and in cohorts of humans with
“early arthritis” (46,47). We are expanding our arrays to
include autoantigens from many additional autoimmune
diseases, including RA, diabetes mellitus, and auto-
immune diseases of the skin. We are using this technol-
ogy to determine the isotype subclass of antibodies
bound to individual antigen features. It is known that
Th1 cytokines (such as IL-12 and interferon-) favor the
production of pathogenic, complement-fixing antibodies
such as IgG1 and IgG3 (in humans), while Th2 cytokines
(such as IL-4 and IL-10) promote class switching to
generate non–complement-fixing IgG4 and IgE antibod-
ies (48,49). Because most studies address global changes
in antibody isotype levels and not reactivity to individual
antigens or epitopes, this technology represents a pow-
erful approach to elucidating the roles of Th1 and Th2
cells (and newly discovered Be1 and Be2 B lymphocytes)
890 ROBINSON ET ALin the generation of antigen-specific B and T lymphocyte
autoreactivity (50).
Several reports have described transcriptional
profiles of tissue from patients with autoimmune dis-
eases, including rheumatoid synovium and brain plaques
from patients with MS (51–54). Interesting findings have
been culled from these large data sets, and the stage is
now set to correlate these findings with the results of
proteomic analysis from the same tissues. Such an
analysis will certainly validate the importance of a subset
of such transcripts in disease pathogenesis, while also
identifying many other proteins as having important
pathogenic roles. These novel proteomics technologies
will enable complex analysis of protein levels within and
between cells (e.g., comparing transcriptional and pro-
tein profiles of distinct lymphocyte populations), as well
as parallel analysis of cytokine and chemokine levels in
biologic fluids. Such studies could identify and further
define critical signaling pathways involved in disease
pathogenesis, cell surface receptors that may serve as
novel targets of drug discovery, and proteomic charac-
teristics of lymphocytes that are anergic, autoreactive, or
regulatory. The powerful combination of genomics and
proteomics has the potential to change forever how we
study the basic biology of autoimmunity.
Application of proteomics technologies to drive
development and selection of antigen-specific therapies
for autoimmune disease. We propose use of autoantigen
arrays to drive development and selection of antigen-
specific therapies for human autoimmune disease. Con-
ventional methods for determining the specificity of
autoimmune responses, including T cell proliferation,
ELISA, and radioimmunoassay analysis, do not enable
large-scale determination of the specificity of auto-
immune responses in individual patients. Antigen arrays
allow simple parallel, multiplex determination of the
specificity of autoimmune responses in individuals and
cohorts of patients. Thus, we propose administration of
antigen-specific therapeutic agents, defined by the bind-
ing specificity of patient autoantibodies. This could be
accomplished utilizing a wide variety of different
antigen-specific therapies. Antigen-specific therapies in-
volve administration of the targeted autoantigen in a
manner that induces immune tolerance to treat autoim-
munity. Such therapies include 1) oral administration of
antigen to induce “oral tolerance” (55), 2) administra-
tion of native peptides via intravenous or other routes
(56,57), 3) administration of altered peptide ligands
(58), 4) administration of whole protein antigens (59), 5)
administration of other biomolecules such as DNA, or
proteins and peptides with posttranslational modifica-
tions (60), and 6) administration of DNA-tolerizing
vaccines encoding the targeted self proteins (61–64).
We anticipate that future antigen-specific thera-
pies based on this strategy will deliver multiple targeted
epitopes or protein antigens as tolerizing agents. Such
therapies could deliver a consensus dominant targeted
epitope or antigen, and could also deliver a cocktail of 20
or more of the consensus targeted epitopes or antigens
to treat patients with a specific disease or subset of that
disease. We are using antigen arrays to guide develop-
ment and selection of antigen-specific DNA-tolerizing
vaccine therapy, a strategy we have termed “reverse
genomics.” We are applying our reverse genomics strat-
egy to develop and select antigen-specific DNA-
tolerizing vaccines to treat EAE (61–63) and collagen-
induced arthritis, a model for RA.
Summary
Array-based autoantibody profiling may provide
a long-awaited platform of technology to determine the
specificity of autoimmune responses in individuals and
cohorts of patients. We believe this technology will drive
development and selection of antigen-specific therapies
for use in the clinic. It is possible, in a manner parallel to
the use of skin testing in the allergy clinic to select
desensitization therapy, that antigen arrays could be
applied to select customized antigen-specific therapy for
individual patients with autoimmune disease. We antic-
ipate that such an antigen array–based strategy will be
initially utilized to develop therapies that could be used
to treat patients with a specific autoimmune disease and
to select patients to receive such therapies. Once
antigen-specific therapies prove safe and effective, and if
inclusion of the exact set of targeted autoantigens in the
therapy proves crucial for efficacy in individual patients,
then customized therapies based on selection of agents
including the targeted autoantigens in individual pa-
tients could be developed in the coming decades.
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